A minimalist approach to transcatheter aortic valve replacement (TAVR) involving local anesthesia appears to have several advantages, according to this new meta-analysis. In addition to shortening times for procedures and lengths of stay in the critical care unit and hospital, lighter sedation may lower the need for transfusions or treatment with inotropes or vasopressors....
This work studies cognitive evolution after transcatheter aortic valve implantation (TAVI). Previous smaller studies reported conflicting results on cognitive function after TAVI. This study prospectively included 229 patients who were ≥70 years old, had undergone TAVI and were assessed using the Mini Mental State Examination before and 6 months after the procedure. Cognitive deterioration or improvement was...
Courtesy of Dr. Santiago F. Coroleu. Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel after percutaneous coronary intervention (PCI) reduces the risk for coronary thrombotic events (CTEs) at the expense of increasing risk for major bleeding (MB). However, the lack of information to accurately predict the occurrence of each event in out-of-hospital patients under...
There are clinics hypothesis that systemic hypothermia (≤34.9) could reduce infarct size if set before reperfusion. Peritoneal lavage had a well-established safety profile and given the large surface area of the bowel may cause rapid hypothermia reducing infarct size. The aim of this study was to evaluate the safety and efficacy of hypothermia induced by...
This record has been created in order to evaluate the results of percutaneous aortic valve replacement in the UK and currently includes more than 4500 patients with 100% follow-up for mortality. The 3-year mortality was 61.6 % beyond the device or path. Atrial fibrillation, renal failure, chronic obstructive pulmonary disease and a EuroSCORE > 18.5...
TVT STS / ACC registrywas developed to obtain data from all patients undergoing percutaneous aortic valve replacement (TAVR) in the United States. The clinical outcome at 30 days was recently published (Macket al, JAMA 2013) but there are few data on the longer-term treatment that is already incorporated in clinical practice in the United States.The...
This randomized, double-blind, placebo-controlled, multicenter work evaluated the potential cardiovascular reduction risk and the long-term safety profile of Aleglitazar, compared with placebo in patients with type 2 diabetes experiencing an acute coronary syndrome. A total of 7226 patients were randomized at 12 weeks post-acute coronary event to receive Aleglitazar 150 ug or placebo. The study...
Coronary artery bypass grafting (CABG) without a cardiopulmonary bypass, (CBP), has increasingly become an alternative to the conventional standard (with pump). However, it is still controversial whether there is a decrease in morbidity and mortality between these two techniques. The aim of this study was to compare these two techniques in a high risk population. ...
The relative benefits and risks of off-pump coronary artery bypass grafting (CABG) as compared with the use of CBP are not clearly defined. The CORONARY trial in 79 centers randomized 4,752 patients in whom CABG was planned with or without CBP. There was no significant difference in the primary end point which was a composite...
Original title: Comparison of 30-Day and 5-Year Outcomes of Percutaneous Coronary Intervention Versus Coronary Bypass Grafting in Patients Aged ≤50 Years. Reference: Fausto Biancari, et al. Am J Cardiology Article in Press. Coronary artery bypass grafting (CABG) is associated with better evolution than percutaneous coronary intervention (PCI), mainly due to left main and multiple vessels re...